JAK2 Inhibitor
Showing 1 - 25 of >10,000
Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)
Recruiting
- Chronic Hand Dermatitis
-
Rochester, New YorkUR Medicine Dermatology College Town
Aug 9, 2022
Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)
Not yet recruiting
- Myelofibrosis
- Moderate Thrombocytopenia
- (no location specified)
Jul 31, 2023
Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS Trial run by the National Heart, Lung, and Blood
Not yet recruiting
- Severe Aplastic Anemia
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 23, 2023
Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)
Not yet recruiting
- Vitiligo
- Effect of Drug
- JAK-2 inhibitor
- Topical corticosteroid
- (no location specified)
Mar 19, 2022
Arteritis, Giant Cell Trial in Rochester (Baricitinib)
Completed
- Arteritis, Giant Cell
-
Rochester, MinnesotaMayo Clinic
Apr 7, 2022
Chronic GVHD, Chronic GVHD Trial run by the NCI (Baricitinib)
Active, not recruiting
- Chronic Graft vs Host Disease
- Chronic Graft-Versus-Host Disease
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 29, 2022
Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)
Recruiting
- Cicatricial Alopecia
- PF-06700841
- Placebo
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Aug 16, 2022
Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)
Recruiting
- Abatacept
- +2 more
- Janus Kinase Inhibitor
- Abatacept
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Jul 5, 2022
Idiopathic Inflammatory Myopathies Trial in London (Baricitinib)
Recruiting
- Idiopathic Inflammatory Myopathies
-
London, United KingdomKing's College Hospital NHS Foundation Trust
May 19, 2022
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of
Recruiting
- BCR-JAK2 Fusion Protein Expression
- +11 more
-
Palo Alto, California
- +3 more
Oct 5, 2022
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)
Active, not recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +11 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 10, 2023
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,
Recruiting
- Acute Myeloid Leukemia
- +8 more
- Decitabine
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 18, 2022
Rheumatoid Arthritis Trial (Baricitinib 4 MG, Placebo)
Not yet recruiting
- Rheumatoid Arthritis
- Baricitinib 4 MG
- Placebo
- (no location specified)
Jul 27, 2023
Active Non-anterior Non-infectious Uveitis Trial (Baricitinib 4 MG)
Not yet recruiting
- Active Non-anterior Non-infectious Uveitis
- Baricitinib 4 MG
- (no location specified)
Dec 7, 2022
Acneiform Eruptions Trial in Shanghai (Cream containing JAK Inhibitor)
Recruiting
- Acneiform Eruptions
- Cream containing JAK Inhibitor
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Jun 20, 2022
Lupus Nephritis Trial in Assiut (Anti JAK1,2)
Active, not recruiting
- Lupus Nephritis
- Anti JAK1,2
-
Assiut, Assuit, EgyptManal Hassanien
Jun 21, 2022
Hemophagocytic Lymphohistiocytoses, Cytokine Storm Trial in Hangzhou (Dexamethasone, Etoposide, Ruxolitinib)
Not yet recruiting
- Hemophagocytic Lymphohistiocytoses
- Cytokine Storm
- Dexamethasone
- +2 more
-
Hangzhou, Zhejiang, ChinaThe Children's Hospital of Zhejiang University School of Medicin
Aug 4, 2022
JAK Inhibition in Ulcerative Colitis
Not yet recruiting
- Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
- JAK inhibitor treatment
- (no location specified)
Jul 11, 2022
Rheumatoid Arthritis Patients Treated With JAK-inhibitor
Recruiting
- Rheumatoid Arthritis
- Upadacitinib <15 MG [Rinvoq]
-
Montpellier, FranceCHU de Montpellier
Jan 12, 2022
Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))
Recruiting
- Advanced Hepatocellular Carcinoma
- Itacitinib (INCB039110)
-
London, United KingdomImperial College Healthcare NHS Trust
Jul 14, 2022
Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)
Completed
- Myelofibrosis
- Imetelstat 4.7 mg/kg
- Imetelstat 9.4 mg/kg
-
Birmingham, Alabama
- +71 more
Aug 17, 2021
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)
Recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 21, 2022